Site Search

1. 71.
   AMP/assets/File/position-statements/2015/AMP-CAPcomments-WPS-DL36398-FINAL.pdf...

   Consider a 50% dose reduction for CYP2C19 poor metabolizers and a 25% dose reduction for CYP2D6 ... should be reduced by 50% in patients who are poor ... pain relief for 98-99% of patients. At the level ... of common adverse events: 30% for constipation, 28% for nausea and 22% for dizziness. (Papaleontiou et al ... of opioids in 25% of cases. They are

   https://www.amp.org/AMP/assets/File/position-statements/2015/AMP-CAPcomments-WPS...
2. 72.
   AMPlificationsApr2015

   Sequencing (NGS) are currently available. Please visit https://www.surveymonkey.com/s/99WB292 and https://www.surveymonkey.com /s/6SBFSCQ ... amjpathol.org/article/S1525-1578%2814%2900245-1/fulltext), a manuscript ... Informatics Subdivision members at https://attendee.gotowebinar.com/register / ... login to your account at https://secure.amp.org/login.cfm

   https://www.amp.org/AMP/assets/File/newsletter/AMPlificationsApr2015.pdf?pass=96
3. 73.
   AMP/assets/File/committees/reports/2025_Annual_Committee_and_Subdivision_Reports...

   Christopher G. Suciu. DOI: https://doi.org/10.1016/j.jmoldx. ... new CPC initiatives are always welcome! Visit https://www.amp.org/clinical-practice/clinical-practice ... payment cuts of up to 15% on approximately 820 widely used tests ... January 2024-December 31, 2024) where 56% of the users were non AMP members and about 35% from outside of the US. • Course

   https://www.amp.org/AMP/assets/File/committees/reports/2025_Annual_Committee_and...
4. 74.
   AMP/assets/File/position-statements/2019/Best_Practices_for_PGx_9_4_2019.pdf?pass=...

   certain conditions are met. 1 https://www.fda.gov/drugs/ ... targeted-therapy-group 2 https://www.fda.gov/drugs ... biomarkers-drug-labeling 3 https://cpicpgx.org/4 https://cpicpgx.org/endorsements/ASSOCIATION ... Heritable Diseases and Conditions” https://www.cdc.gov/mmwr ... ShowProperty?nodePath=/UCMCON/Contribution%20Folders/DctmContent/education/OnlineCourseContent

   https://www.amp.org/AMP/assets/File/position-statements/2019/Best_Practices_for_...
5. 75.
   AMP/assets/File/position-statements/2019/Best_Practices_for_PGx_9_4_2019.pdf?pass=...

   certain conditions are met. 1 https://www.fda.gov/drugs/ ... targeted-therapy-group 2 https://www.fda.gov/drugs ... biomarkers-drug-labeling 3 https://cpicpgx.org/4 https://cpicpgx.org/endorsements/ASSOCIATION ... Heritable Diseases and Conditions” https://www.cdc.gov/mmwr ... ShowProperty?nodePath=/UCMCON/Contribution%20Folders/DctmContent/education/OnlineCourseContent

   https://www.amp.org/AMP/assets/File/position-statements/2019/Best_Practices_for_...
6. 76.
   AMP/assets/File/awards/technologist/WinningAbstracts_Nov2013.pdf?pass=72

   The most common cnLOH is 13q seen in seven patients (21%), followed by 1p and 11p in ... the 33 patients with cnLOH (52%) achieved CR; with an average CR ... poor or intermediate cytogenetic risk, 100% with 21q cnLOH achieved CR and ... with 13q cnLOH, seen in 100% of patients (6/6) tested. Presence ... was expressed in 27/52 (51%) BRAF-mutated sporadic CRC and 8

   https://www.amp.org/AMP/assets/File/awards/technologist/WinningAbstracts_Nov2013...
7. 77.
   AMP/assets/File/advocacy/AMPResponseFDACaseReportFinal.pdf?pass=79

   This means that only 0.016% were falsely positive. If FDA’s “ ... to note that less than 1% of Oncotype DX tests are performed ... Med. 2015; 373: 2005-2014. 13 https://clinicaltrials.gov/show/NCT00310180 Accessed December ... a false positive rate of 0.08%.24 The non-invasive test that ... which is found in approximately 20% of patients with resistance to older

   https://www.amp.org/AMP/assets/File/advocacy/AMPResponseFDACaseReportFinal.pdf?p...
8. 78.
   AMP/assets/File/position-statements/2015/AMPResponseFDACaseReportFinal.pdf?pass=78

   This means that only 0.016% were falsely positive. If FDA’s “ ... to note that less than 1% of Oncotype DX tests are performed ... Med. 2015; 373: 2005-2014. 13 https://clinicaltrials.gov/show/NCT00310180 Accessed December ... a false positive rate of 0.08%.24 The non-invasive test that ... which is found in approximately 20% of patients with resistance to older

   https://www.amp.org/AMP/assets/File/position-statements/2015/AMPResponseFDACaseR...
9. 79.
   Microsoft Word - AMP comments microarray063010_final.doc

   Monosomy 1q41-q42 1q41-q42 multiple 1.17Mb 0.5% ~99% 0.07% of MR/DD patients ... 2p15 2p15 multiple 570kb 0.0% ~99% 1.2% of MR/DD patients Rajcan ... 15q13.3 15q13.3 multiple 1.5Mb 0.5% ~99% 0.3% of MR/DD patients Sharp ... 15q24 15q24 multiple 1.7Mb 0.5% ~99% 0.3% of MR/DD patients Sharp ... 16p11.2 – p12.2 multiple 555kb 0.0% ~99% 1% of autism patients Ballif et

   https://www.amp.org/AMP/assets/File/position-statements/2010/AMPcommentsmicroarr...
10. 80.
    AMP/assets/File/education/case-studies/0321_45-47_AMPcase-reprint-LowRes.pdf?pass=...

    A p.E571K62%SF3B1c.2098A>G p.K700ENRc.1873C>T p.R625C46%BTKc.1442G>C p.C481SNRNot detectedTP53c.743G>A p.R248Q5%c.721T>C p.S241P85%c.746G>A p.R249K5%BTG1Not detectedc.123C>G ... sample using our institution’s 1,385-gene panel (full gene list at: https://j.mp/3oYr2bf). This assay reports single nucleotide variants, indel, copy number, and

    https://www.amp.org/AMP/assets/File/education/case-studies/0321_45-47_AMPcase-re...